George Yancopoulos Net Worth

George Yancopoulos has an estimated net worth of $1.8 billion, according to Forbes Real-Time Billionaires, George Yancopoulos profile (figures as of October 20, 2026). That is up from $1.2 billion in 2019.

George Yancopoulos is an American biomedical scientist best known as the co-founder, president and chief scientific officer of Regeneron Pharmaceuticals. He earned both his M.D. and Ph.D. from Columbia University in 1987 and became a biology professor by age 28. In 1989, he left academia to join Regeneron in its early days. He later took on a larger leadership role at the company while continuing to work on drug discovery and development.

His wealth comes from Regeneron, where Forbes says he owns about 1% of the company’s stock. At Regeneron, he led the invention of FDA-approved drugs and helped build a technology platform designed to create more treatments. Background facts also credit him with core technologies such as TRAP, VelociGene, and VelocImmune. Forbes puts his net worth at $1.8 billion on its real-time billionaires tracker as of October 20, 2026.

How George Yancopoulos makes his money

Yancopoulos built his fortune through science and leadership at Regeneron. The biotech firm was cofounded by Leonard Schleifer in 1988, and Yancopoulos joined the next year. He became a key figure in the company’s research work and later served as president and chief scientific officer. Forbes says he owns about 1% of Regeneron stock, so his wealth is closely tied to the company’s value and long-term performance in pharmaceuticals.

His career is unusual because his scientific work connects directly to commercial results. Forbes says he led the invention of FDA-approved drugs and a technology platform meant to keep producing more. Background facts also describe him as a principal inventor and developer of Regeneron treatments and foundational tools for target and drug development. He also holds more than 100 patents. That mix of research, patents, leadership, and stock ownership is what made him a billionaire.

Forbes estimates over time

Forbes has tracked Yancopoulos as a self-made billionaire in healthcare, with wealth tied to pharmaceuticals. Its estimates went from $1.2 billion in 2019 to $1.1 billion in 2020 and stayed at $1.1 billion in 2021. The figure then climbed to $1.4 billion in 2022 and $1.6 billion in 2023. In 2024, Forbes estimated his fortune at $2.1 billion before lowering it to $1.6 billion in 2025.

The latest Forbes figures show another increase. Forbes listed him at $1.8 billion on the 2026 World’s Billionaires List, and the same $1.8 billion appeared on its real-time tracker in October 2026. The money story in the available facts is straightforward: his stake in Regeneron matters most. Since Forbes says he owns about 1% of the company, changes in that holding can push the estimate up or down over time.